Dutch health minister attacks Novartis over orphan drug price hike

05:54 EST 15 Jan 2019 | Pharmafile

Dutch health minister Bruno Bairns has called for a meeting with Swiss multinational Novartis after the multibillion-dollar firm introduced a five-fold price hike on cancer drug Lutathera.

The call has come following Novartis’ acquisition of nuclear medicine specialist Advanced Accelerator Applications. The buyout gave Novartis the rights to orphan drug. However Bruins has accused Novartis of using the drug’s market exclusivity to jack up the price.

read more

Original Article: Dutch health minister attacks Novartis over orphan drug price hike

More From BioPortfolio on "Dutch health minister attacks Novartis over orphan drug price hike"